BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 27178030)

  • 21. Clinical and economic implications of adding HPV tests to the routine cytology follow-up and management of patients with histologically defined cervical intraepithelial neoplasia grade 1.
    Gamzu R; Almog B; Levin I; Fainaru O; Niv J; Lessing JB; Bar-Am A
    Gynecol Oncol; 2002 Aug; 86(2):129-33. PubMed ID: 12144817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK.
    Brown RE; Breugelmans JG; Theodoratou D; Bénard S
    Curr Med Res Opin; 2006 Apr; 22(4):663-70. PubMed ID: 16684427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytology and human papillomavirus screening test results associated with 2827 histopathologic diagnoses of cervical intraepithelial neoplasia 2/3.
    Zhao C; Amin M; Weng B; Chen X; Kanbour-Shakir A; Austin RM
    Arch Pathol Lab Med; 2013 Jul; 137(7):942-7. PubMed ID: 23050808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
    Tay SK; Lin LE; Goh RC
    Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resource Use and Cost of Treating Human Papillomavirus-Related Lesions in Japanese Women.
    Mizukami A; Kaise T; Van Kriekinge G
    Value Health Reg Issues; 2018 May; 15():56-62. PubMed ID: 29474179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Results and cost evaluation of triage with high risk HPV test in cervical cancer screening. A pilot study in Piedmont (North-West Italy)].
    Magnani C; Gillio Tos A; De Marco L; Calvia M; Cipelletti A; Bestagini P; Pagano E; Segnan N; Ronco G
    Epidemiol Prev; 2012; 36(2):88-94. PubMed ID: 22706358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extended Human Papillomavirus Genotype Distribution and Cervical Cytology Results in a Large Cohort of Chinese Women With Invasive Cervical Cancers and High-Grade Squamous Intraepithelial Lesions.
    Jiang W; Marshall Austin R; Li L; Yang K; Zhao C
    Am J Clin Pathol; 2018 May; 150(1):43-50. PubMed ID: 29746625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
    Zhao X; Wu Q; Wang X; Fu Y; Zhang X; Tian X; Cheng B; Lu B; Yu X; Lan S; Lu W; Ma D; Cheng X; Xie X
    Clin Microbiol Infect; 2018 Dec; 24(12):1322-1327. PubMed ID: 29518562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SNIPER: a novel assay for human papillomavirus testing among women in Guizhou, China.
    Belinson SE; Wulan N; Li R; Zhang W; Rong X; Zhu Y; Wu R; Belinson JL
    Int J Gynecol Cancer; 2010 Aug; 20(6):1006-10. PubMed ID: 20683409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.
    Sørbye SW; Fismen S; Gutteberg TJ; Mortensen ES; Skjeldestad FE
    BMJ Open; 2016 Aug; 6(8):e011981. PubMed ID: 27515759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
    Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
    Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Costs of population cervical cancer screening program in Poland between 2007-2009].
    Spaczyński M; Karowicz-Bilinska A; Kedzia W; Molińska-Glura M; Seroczyński P; Januszek-Michalecka L; Rokita W; Nowak-Markwitz E
    Ginekol Pol; 2010 Oct; 81(10):750-6. PubMed ID: 21117303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
    Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
    BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of Specific Types of Human Papiloma Virus in Cervical Intraepithelial Lesions and Cervical Cancer in Macedonian Women.
    Aleksioska-Papestiev I; Chibisheva V; Micevska M; Dimitrov G
    Med Arch; 2018 Feb; 72(1):26-30. PubMed ID: 29416214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
    Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
    J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Searching for an ideal cervical cancer screening model to reduce false-negative errors in a country with high prevalence of cervical cancer.
    Song T; Seong SJ; Lee SK; Kim BR; Ju W; Kim KH; Nam K; Sim JC; Kim TJ
    J Obstet Gynaecol; 2020 Feb; 40(2):240-246. PubMed ID: 31340702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Previous Papanicolaou and Hybrid Capture 2 human papillomavirus testing results of 5699 women with histologically diagnosed cervical intraepithelial neoplasia 2/3.
    Wu T; Chen X; Zheng B; Li J; Xie F; Ding X; Zeng Z; Zhao C
    J Am Soc Cytopathol; 2019; 8(4):206-211. PubMed ID: 31272603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis.
    Arbyn M; Verdoodt F; Snijders PJ; Verhoef VM; Suonio E; Dillner L; Minozzi S; Bellisario C; Banzi R; Zhao FH; Hillemanns P; Anttila A
    Lancet Oncol; 2014 Feb; 15(2):172-83. PubMed ID: 24433684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefits and costs of using HPV testing to screen for cervical cancer.
    Mandelblatt JS; Lawrence WF; Womack SM; Jacobson D; Yi B; Hwang YT; Gold K; Barter J; Shah K
    JAMA; 2002 May; 287(18):2372-81. PubMed ID: 11988058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme.
    Anttila A; Kotaniemi-Talonen L; Leinonen M; Hakama M; Laurila P; Tarkkanen J; Malila N; Nieminen P
    BMJ; 2010 Apr; 340():c1804. PubMed ID: 20423964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.